home / stock / bmnd:cc / bmnd:cc news

BMND:CC News and Press, BIOMIND LABS INC.

Stock Information
Company Name: BIOMIND LABS INC.
Stock Symbol: BMND:CC
Market: AQNC
Menu
BMND:CC BMND:CC Quote BMND:CC Short BMND:CC News BMND:CC Articles BMND:CC Message Board
Get BMND:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
BMND:CC - Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways

TORONTO, ON / ACCESSWIRE / July 18, 2024 / Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND) (OTC PINK:BMNDF) (FRA:3XI) , a leading biotech company dedicated to developing the next-generation of pharmaceuticals targeting the root causes of neurological disorders, announced the ...
BMND:CC - Canadian Investment Regulatory Organization Trade Resumption - BMND

Canadian Investment Regulatory Organization Trade Resumption - BMND Canada NewsWire TORONTO , June 4, 2024 /CNW/ - Trading resumes in: Company: BIOMIND LABS INC. NEO Exchange Symbol: BMND All Issues: Yes Resumption (ET): 9:30 AM CIRO can ...

BMND:CC - Canadian Investment Regulatory Organization Trading Halt - BMND

Canadian Investment Regulatory Organization Trading Halt - BMND Canada NewsWire TORONTO , April 9, 2024 /CNW/ - The following issues have been halted by CIRO: Company: BIOMIND LABS INC. NEO Exchange Symbol : BMND All Issues: Yes Reason: Cease Tra...

BMND:CC - Biomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer's Disease

Biomind Labs Inc. (“ Biomind ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeti...
BMND:CC - Biomind Labs Provides Corporate Update

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...

BMND:CC - Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...

BMND:CC - Biomind Announces Voting Results From the 2023 Annual Meeting of Shareholders

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...
BMND:CC - Biomind Labs Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer's Disease With a Proprietary formulation Based On 5-MeO-DMT

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...

BMND:CC - Biomind Labs Reaches High Purity and Yield of DMT Through an Optimized Extraction Method for Its New Chemical Entity Triptax(TM)

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by ta...

BMND:CC - Biomind Labs Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer's Disease

Biomind Labs Inc. (“ Biomind Labs ” or the “ Company ”) ( NEO: BMND ) ( OTC: BMNDF ) ( FSE: 3XI ), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric...
Next 10